| [1] |
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
|
| [2] |
Cao W, Chen HD, Yu YW, et al. Changing profiles of cancer burden worldwide and in China: A secondary analysis of the global cancer statistics 2020[J]. Chin Med J (Engl), 2021, 134(7): 783-791.
|
| [3] |
Yang J, Nie J, Ma X, et al. Targeting PI3K in cancer: mechanisms and advances in clinical trials[J]. Mol Cancer, 2019, 18(1): 26.
|
| [4] |
Dornan GL, Burke JE. Molecular mechanisms of human disease mediated by oncogenic and primary immunodeficiency mutations in class ⅠA phosphoinositide 3-kinases[J]. Front Immunol, 2018, 9: 575.
|
| [5] |
Revathidevi S, Munirajan AK. Akt in cancer: mediator and more[J]. Semin Cancer Biol, 2019, 59(1): 80-91.
|
| [6] |
Liu R, Chen Y, Liu G, et al. PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers[J]. Cell Death Dis, 2020, 11(9): 797.
|
| [7] |
Kim CG, Lee H, Gupta N, et al. Role of forkhead box class O proteins in cancer progression and metastasis[J]. Semin Cancer Biol, 2018, 50: 142-151.
|
| [8] |
Ren G, Yang EJ, Tao S, et al. MDM2 inhibition is synthetic lethal with PTEN loss in colorectal cancer cells via the p53-dependent mechanism[J]. Int J Biol Sci, 2023, 19(11): 3544-3557.
|
| [9] |
Fruman DA, Chiu H, Hopkins BD, et al. The PI3K pathway in human disease[J]. Cell, 2017, 170(4): 605-635.
|
| [10] |
Zhang J, Zheng J, Yang Y, et al. Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer patients: analysis of 1,110 cases[J]. Sci Rep, 2015, 5: 18678.
|
| [11] |
Ye ZL, Qiu MZ, Tang T, et al. Gene mutation profiling in Chinese colorectal cancer patients and its association with clinicopathological characteristics and prognosis[J]. Cancer Med, 2020, 9(2): 745-756.
|
| [12] |
Voutsadakis IA. The landscape of PIK3CA mutations in colorectal cancer[J]. Clin Colorectal Cancer, 2021, 20(3): 201-215.
|
| [13] |
Myer PA, Lee JK, Madison RW, et al. The genomics of colorectal cancer in populations with African and European ancestry[J]. Cancer Discov, 2022, 12(5): 1282-1293.
|
| [14] |
Ogino S, Lochhead P, Giovannucci E, et al. Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology[J]. Oncogene, 2014, 33(23): 2949-2955.
|
| [15] |
Fu X, Lin H, Fan X, et al. The spectrum, tendency and predictive value of PIK3CA mutation in Chinese colorectal cancer patients[J]. Front Oncol, 2021, 11: 595675.
|
| [16] |
Jin J, Shi Y, Zhang S, et al. PIK3CA mutation and clinicopathological features of colorectal cancer: A systematic review and meta-analysis[J]. Acta Oncol, 2020, 59(1): 66-74.
|
| [17] |
Guo F, Gong H, Zhao H, et al. Mutation status and prognostic values of KRAS, NRAS, BRAF and PIK3CA in 353 Chinese colorectal cancer patients[J]. Sci Rep, 2018, 8(1): 6076.
|
| [18] |
Hall D, Benndorf RA. Aspirin sensitivity of PIK3CA-mutated colorectal cancer: potential mechanisms revisited[J]. Cell Mol Life Sci, 2022, 79(7): 393.
|
| [19] |
Chen H, Qi Q, Wu N, et al. Aspirin promotes RSL3-induced ferroptosis by suppressing mTOR/SREBP-1/SCD1-mediated lipogenesis in PIK3CA-mutant colorectal cancer[J]. Redox Biol, 2022, 55: 102426.
|
| [20] |
Gray RT, Cantwell MM, Coleman HG, et al. Evaluation of PTGS2 expression, PIK3CA mutation, aspirin use and colon cancer survival in a population-based cohort study[J]. Clin Transl Gastroenterol, 2017, 8(4): e91.
|
| [21] |
Zhou J, Ji Q, Li Q. Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies[J]. J Exp Clin Cancer Res, 2021, 40(1): 328.
|
| [22] |
Mao C, Yang ZY, Hu XF, et al. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis[J]. Ann Oncol, 2012, 23(6): 1518-1525.
|
| [23] |
Martins M, Mansinho A, Cruz-Duarte R, et al. Anti-EGFR therapy to treat metastatic colorectal cancer: not for all[J]. Adv Exp Med Biol, 2018, 1110: 113-131.
|